RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A. Chapman, Kwee Yong, Fenella Willis et al.|Blood|2018Cited by 20
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Kwee Yong, María Cuadrado et al.|British Journal of Haematology|2021Cited by 15
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon StudyKwee Yong, Roger G. Owen, Rakesh Popat et al.|Blood|2019Cited by 8
Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)Rakesh Popat, Kwee Yong, James D. Cavenagh et al.|Blood|2014Cited by 1
RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based TherapyJonathan Sive, Michael A. Chapman, John C. Ambrose et al.|Blood|2016Cited by 0